Kornimate/medical-research-clean huggingface dataset:
the effectiveness of different exercise approaches in biceps brachii long head tendinopathy

Conditions: Sports Physical Therapy; Tendinopathy

Summary: this study was planned to analyze the changes in tendon cross-sectional area and shoulder pain with different exercise approaches applied in biceps brachii long head tendinopathy.

there are different conservative treatment options for biceps brachii long head tendinopathy. however, the exercise approaches that can be applied for biceps brachii tendinopathy are not clear in the literature. this study aims to investigate the effectiveness of exercises that include 12 weeks of eccentric training or combined exercise approaches.

Eligibility criteria:
inclusion criteria: * having shoulder pain lasting 3 months or more * without a history of surgery, having a diagnosis of shoulder rotator cuff tendinopathy, rotator cuff stage 1-2 tear or subacromial impingement, and having been diagnosed with secondary biceps long head tendinopathy by a physician * pain level during activity \> 3 according to the visual analog scale * patients who have been informed about the study and have given written consent to participate in the study will be included in the study. exclusion criteria: * acute shoulder injury * history of shoulder and cervical surgery * limitation of passive range of motion * history of local corticosteroid injection within the last 12 months * patients who cannot comply with the exercise program will be excluded from the study.

Keywords: biceps brachii tendinopathy tendon cross-sectional area shoulder pain
sleep and girls' emotions study

Conditions: Depression

Summary: this study evaluates whether increasing sleep duration can increase neural and behavioral response to rewards and decrease depressive symptoms in 18- to 22-year-old women with insufficient sleep and depressive symptoms.


Eligibility criteria:
inclusion criteria: * insufficient sleep (total sleep time \< 8 hours per night, with sleepiness scores ≥ 6 on the epworth sleepiness scale or ≥ 16 on the promis sleep related impairment scale) * symptoms of depression (≥ 15 on the center for epidemiological studies for depression scale) exclusion criteria: * current insomnia, hypersomnia, sleep disordered breathing, sleep movement disorder, or circadian rhythm disorder * history of head injury with loss of consciousness within the past two years * history of head injury with loss of consciousness two or more years ago and meet criteria for post concussion syndrome * neurological disorder * use of psychiatric medications * current psychotic symptoms * active suicidal ideation * conditions that are contraindicated for mri (e.g., ferromagnetic material in the body) * meet criteria for current substance use disorder with greater than mild severity
effect of roflumilast in chronic obstructive pulmonary disease (copd) patients treated with tiotropium: the helios study (by217/m2-128)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (copd) during concomitant administration of tiotropium. the study duration will last up to 28 weeks. the study will provide further data on safety and tolerability of roflumilast.


Eligibility criteria:
main inclusion criteria: * history of copd for at least 12 months prior to baseline visit and chronic productive cough for 3 months in each of the 2 years prior to baseline visit * fev1/fvc ratio (post-bronchodilator) ≤ 70% * fev1 (post-bronchodilator) between ≥ 40% and ≤ 70% of predicted * treated with tiotropium for at least 3 months before enrollment * at least 28 puffs of rescue medication during last week prior to randomization main exclusion criteria: * copd exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit

Keywords: copd roflumilast
phase ii trial evaluating irinotecan and capecitabine relapsed/refractory upper gi tumours

Conditions: Upper Gastrointestinal Tumours

Summary: the objective of this study is to assess the efficacy and toxicity of a 3 weekly regimen containing irinotecan combined with capecitabine in the setting of relapsed or refractory upper gastrointestinal tumours. patients with locally advanced or metastatic adenocarcinoma or squamous cell carcinoma originating from the oesophagus, oesophagogastric junction or stomach who have previously received chemotherapy and have either failed to respond or who have relapsed within 3 months after an initial response will be eligible for treatment in this study. the response rate, failure-free survival and overall survival of treated patients will be evaluated. toxicity and quality of life will also be monitored closely.


Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma or squamous cell carcinoma of oesophagus, o-g junction and stomach, not amenable to surgical resection. * bidimensionally measurable disease, or unidimensional measurable disease assessable by ct scanning, not within previously irradiated areas. * patients with progressive disease during previous chemotherapy treatment or within three months of stopping treatment. * at least one previous chemotherapy regimen, given within 3 months prior to inclusion in this study. * no previous exposure to irinotecan. * adequate bone marrow function with platelets \>100 x 109/l; wbc \> 3 x 109/l; neutrophils \> 1.5 x 109/l at the time of study entry. * satisfactory renal function. creatinine clearance (measured by cockcroft and gault) \>50ml/min and cr \<135. * satisfactory liver function: * in the absence of liver metastases: bilirubin \< 1.25n (n=upper limit of normal range) hepatic transaminases \< 2.5n prothrombin time \< 1.5n * in the presence of liver metastases: bilirubin \< 1.5n hepatic transaminases \< 5n prothrombin time \< 1.5n * no uncontrolled medical condition * no previous malignant disease except for non-melanotic skin cancer or in-situ carcinoma of the uterine cervix. * ecog performance status of 0, 1 or 2. * predicted life expectancy of \> 3 months. * adequate contraceptive precautions * informed written consent exclusion criteria: * medical or psychiatric conditions resulting in inability of patient to give written consent. * ecog performance status \>2 * intracerebral metastases or meningeal carcinomatosis * unresolved bowel obstruction * creatinine clearance \ 135 * uncontrolled angina pectoris, heart failure (new york heart classification 3 or 4). * pregnancy/lactation * previous malignancy other than adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ.
a study of ly3041658 in participants with skin diseases

Conditions: Skin Diseases; Psoriasis

Summary: the main purpose of this study is to investigate the safety and tolerability of the study drug known as ly3041658 in participants with certain types of skin diseases. the study will measure how the body absorbs, breaks down and gets rid of ly3041658. it will last about 127 days for each participant, not including screening. this study is for research purposes only, and is not intended to treat any medical condition.


Eligibility criteria:
inclusion criteria: * investigator confirmed diagnosis of certain skin diseases for at least 6 months. * active skin lesions that are not responding to standard therapies. * willing to undergo pre- and post-treatment skin biopsies of lesions. exclusion criteria: - have other skin diseases that may interfere with evaluation of the specified skin disease being studied.
suture-tight™ first-in-human safety and performance study

Conditions: Aortic Aneurysm, Abdominal

Summary: single center, open label, prospective, single-arm, first-in-human (fih), pre-market clinical study with the objective of validating the safety and performance of the suture-tight™ suture delivery system in an evar procedure.

single center, study conducted at the prince of wales private hospital in randwick, australia. up to 6 subjects may be enrolled. 1 to 3 subjects will complete initial enrollment and be followed for 30-days evaluating procedure and device safety. additional subjects may be enrolled following the safety review to complete the 6-subject study. all subjects will be followed for six (6) months. subjects meeting all inclusion and exclusion criteria will be consented to receive an elective endovascular aortic aneurysm repair (evar) with graft anchoring utilizing the suture-tight device. procedure and device safety and performance will be evaluated at 1- and 6-months by completing ct scans and kub x-rays. data may be used to support a pivotal study of the investigational device and future global regulatory submissions.

Eligibility criteria:
inclusion criteria: * currently scheduled for an elective endovascular repair of an abdominal aortic aneurysm (aaa) by evar with ct scan from within last 4 months. acceptable aaa parameters include: aaa ≥ 5.0 cm in diameter or aaa ≥ 4.5 cm in diameter with an increase of ≥ 0.5 cm within the past 6-months or ≥ 1.0 cm over the past 12-months * neck diameter, length and angulation that meets labeling requirements for the endograft used * successful evar graft placement with no evidence of evar-associated serious adverse event. exclusion criteria: * mycotic or inflammatory aaa * prior surgical repair of an aaa * renal dialysis or significant chronic renal failure * evidence of recent acute coronary disease, thrombotic disease, or cerebral infarct * pregnancy

Keywords: evar aaa anchor
treatment with the ketone body 3-hydroxybutyrate in patients with cardiogenic shock

Conditions: Cardiogenic Shock

Summary: background cardiogenic shock is a life-threatening state of acute heart failure with severely depressed blood pressure and organ perfusion. the 30-day mortality is reported as high as 50%. to date, no randomized trial has documented a survival benefit of any medical treatment in this patient group. in a first-in-man study the investigators have recently discovered that treatment with ketone bodies increases cardiac output by 2 liters per minute. objective the present study aims to examine the direct effects of ketone body supplements on the heart function in patients hospitalized with cardiogenic shock. also, the aim is to determine the relative need for medical circulatory support following ketone body supplement. design a randomized double-blind cross-over study of the hemodynamic effect of enteral ketone ester versus placebo in 12 patients with cardiogenic shock methods right heart catheterization will be installed to monitor cardiac pressures and output. the investigators will observe heart function with transthoracic echocardiography. blood- and urine samples will be analyzed for electrolytes, energy substrates and vasoactive substances. organ perfusion is to be examined by renal ultrasonography and near-infrared spectroscopy for measuring cerebral and peripheral circulation. perspectives this investigation may grant essential knowledge on ketosis in cardiogenic shock. this may lead to larger clinical trials, and hopefully a new and better treatment for patients with cardiogenic shock.


Eligibility criteria:
inclusion criteria: * ongoing treatment with inotropes and/or vasopressors because of cardiogenic shock as judged by the clinicians * patients are required at some point in time to have had \> 1 of the following: systolic blood pressure \< 90 mmhg; arterial blood lactate ≥ 2.5mmol/l; organ hypoperfusion (e.g. urinary output \< 0.5 ml/kg/hour or svo2 \<55% with normal pao2 and hgb) * lvef \< 40% * age ≥ 18 years exclusion criteria: * other primary causes of shock (hypovolemia, hemorrhage, severe infection or sepsis, pulmonary embolism or anaphylaxis), * shock due to mechanical complication to myocardial infarction (papillary muscle rupture, rupture of the ventricular septum or rupture of free wall) * intermacs level 1 or 2 \[18\] with unstable or sliding hemodynamics on inotropes/vasopressors * use of or probable need for mechanic circulatory support (e.g. left ventricular assistant device, impella, extracorporeal membrane oxygenation) * recent post-cardiotomy cardiogenic shock (defined as thoracic surgery with the last 3 days) * inability to position a nasogastric tube * severe gastroparesis or abdominal distension

Keywords: ketone bodies β-hydroxybutyrate
medtronic market-released df4 lead imaging

Conditions: Tachycardia

Summary: the medtronic market-released df4 lead imaging study is a prospective, non-randomized study, multi-center clinical investigation. the purpose of this clinical investigation is to collect high quality medical images of the medtronic market-released df4 lead in the shoulder and heart. images collected during the study will allow for lead design and testing processes better tailored to the implanted environment.


Eligibility criteria:
inclusion criteria: * patients greater than 18 years of age. * patients able and willing to attend imaging session. * patients able and willing to give informed consent. * patients with an implanted device/lead(s) for a minimum of 3 months. exclusion criteria: * subjects who require a legally authorized representative to obtain consent. * subjects with exclusion criteria required by local law (e.g. age, breastfeeding * pregnant women, or women of child bearing potential and who are not on a reliable form of birth control.
effects of antiplatelet and antioxidant agents on drusen progression: a pilot, prospective cohort study

Conditions: Dry Age-related Macular Degeneration

Summary: the aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (n-acetylcysteine 600 mg/day) in a dry amd patient with large drusen. participants will divided in to three groups. * participants who were already taking low dose antiplatelet medications. * participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * participants does not use any medications.


Eligibility criteria:
inclusion criteria: * dry amd with at least 1 large drusen. according to the areds study, large drusen have a size of more than 125 micron. * patients can evaluate sd-oct (spectral domain optical coherence tomography), oct angiography, and best-corrected visual acuity. * age range: 50-85 years * patients who have previously used antiplatelet drugs. exclusion criteria: * patient with advanced amd, such as geographic atrophy, neovascular complications (choroidal neovascularization) * patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema. * patient with a history of intravitreal anti-vegf injection or macular laser. * patient using ssris, snris, azole, nsaids, dual antiplatelet, anticoagulant medications.
image supported lead placement in crt

Conditions: Heart Failure

Summary: cardiac resynchronization therapy (crt) is an established pacemaker therapy for patients with symptomatic chronic heart failure, but is hampered by a non-response rate of 30-40%. optimising left ventricular (lv) lead placement is the cornerstone of improving treatment. the optimal location for the lead is remote from scar but within segments demonstrating late electromechanical activation. the present study aims to investigate the efficacy and clinical effect of the use of real-time guided lead placement using cardiac mri and fluoroscopy in a blinded, multicenter, randomized controlled trial.


Eligibility criteria:
inclusion criteria: * heart failure with lv ejection fraction ≤ 35%; * new york heart association class ii, iii, or iv (ambulatory); * optimal medical treatment that is tolerable; * left bundle branch block (lbbb) and qrs ≥ 130 ms, or non-lbbb and qrs ≥ 150 ms. exclusion criteria: * pregnancy or lactation; * subjects with impaired renal function (severe renal insufficiency, gfr \< 30 ml/min/1.73m2); * atrial fibrillation or atrial fibrillation during mri * documented allergic reaction to gadolinium; * impossibility to undergo an mri scan; * participation in another clinical study that prohibits any procedures other than standard.

Keywords: cardiac resynchronization therapy image-guided therapy lead placement mri
patient acceptance and satisfaction of teledermoscopy in general practice in a belgian rural area

Conditions: Skin Cancer; Patient Acceptance of Health Care; Patient Satisfaction

Summary: the aim objective of this work is to assess the characteristics of patients for whom teledermoscopy could be suitable for the detection of potential skin cancers, within a population of rural general medicine in the south of hainaut, by means of a mixed quantitative and qualitative study corresponding respectively: * to identify patients' knowledge of skin cancers, their skin monitoring habits, and their acceptability of new telemedicine tools such as teledermoscopy ("part 1"). * to evaluate the satisfaction and expectations of those who benefit from teledermoscopy ("part 2").


Eligibility criteria:
inclusion criteria: * adults ( \> 18y) * french speaking patient exclusion criteria: * illiterate patients * demented patients * non-french speaking patients * minors.

Keywords: skin cancer screening general practice teledermoscopy patient satisfaction and acceptance
predictors of postoperative atrial fibrillation after cabg

Conditions: Coronary Artery Disease; Atrial Fibrillation New Onset

Summary: this observational study aims to identify the determinants or predictors of postoperative atrial fibrillation (poaf) in patients who have undergone coronary artery bypass grafting (cabg). the study will compare two cohorts: patients who developed poaf and those who did not (non-poaf), with the aim of improving postoperative care, reducing complications, and refining patient risk stratification.

demographics (age, sex, ethnicity), lifestyle factors (smoking, alcohol, physical activity), and medical history (diabetes, hypertension, prior heart diseases) will be recorded. surgical procedure details (number of grafts, use of intraoperative devices), anesthesia, and medications administered. levels of inflammatory markers, cardiac-specific markers, and other relevant biomarkers at baseline and postoperatively. other complications besides poaf, hospital length of stay, icu admission, readmission rate, and mortality will also be monitored.

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older. * patients who underwent cabg. exclusion criteria: * patients with a history of preoperative atrial fibrillation or other significant arrhythmias. * patients who underwent other concurrent cardiac procedures (e.g., valve surgery) in addition to cabg. * patients who cannot provide informed consent or lack adequate follow-up information.

Keywords: coronary artery bypass grafting postoperative atrial fibrillation
study to investigate the effect of an oral diamine oxidase substitution (daosin) in histamine intolerant patients on the low endogenous diamine oxidase serum activity

Conditions: Food Intolerance; Histamine Intolerance

Summary: daosin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake. in this uncontrolled, interventional pilot study the effect of an oral diamine oxidase substitution (daosin) on the reduced endogenous diamine oxidase activity in histamine intolerant patients will be examined. patients with a low endogenous diamine oxidase activity (below 10 units/ml) take daosin for one month 3 times a day. during this month the diamine oxidase activity is tested biweekly. afterwards a follow up period of one month without taking daosin follows. again the diamine oxidase activity is tested biweekly.


Eligibility criteria:
inclusion criteria: * diamine oxidase activity \< 10 u/ml * \>= 2 symptoms of histamine intolerance after consumption of histamine containing food * 18 to 80 years * no lactose intolerance * no fructose intolerance * no tissue transglutaminase antibodies in serum exclusion criteria: * pregnancy and nursing * cardiopathy * instable hypertonie * asthma bronchial * lactose intolerance, fructose intolerance, coeliac disease * severe liver and kidney diseases * known food and other allergies * participation in clinical study the last 4 weeks * recent (3 months) operation affecting the gastrointestinal tract * maligne, infectious or autoimmune gastrointestinal diseases (e.g. ibd) * taking histamine liberating drugs on a regular basis * taking diamine oxidase inhibiting drugs on a regular basis * taking diamine oxidase supplements on a regular basis in the last 4 weeks * h1 blocker or montelukast therapy 4 month before study start * taking anti histaminica * taking zinc preparations * drug, alcohol, pharmaceutical abuses * heavy smoking (\>15 cigarettes a day) * known hiv infection * known acute or chronic hepatitis b and c infection

Keywords: food intolerance histamine intolerance diamine oxidase dao daosin
long-term outcome of newborns with an isolated small cerebellum

Conditions: Cerebellar Hypoplasia

Summary: the decreased cerebellar biometry during second and third trimester ultrasound examination is the main parameter to diagnoses cerebellar and pontocerebellar hypoplasia. investigators already described that a transverse cerebellar diameter (tcd) below the 5th centile at second or third trimester scan is related to a high rate of fetal malformations, severe intrauterine restriction in growth, chromosomal anomalies and genetic disorders, therefore when facing a tcd below the 5th centile, patients should be referred for oriented sonogram, fetal mri (magnetic resonance imaging) and fetal karyotyping. however, prenatal counseling in case of an isolated decreased cerebellar biometry remains challenging since there are no data in the literature regarding the neurodevelopmental outcome of these newborns. the aim of this work is to evaluate the neurodevelopmental outcome of newborns with a prenatal isolated decreased cerebellar biometry, in order to improve prenatal counseling.


Eligibility criteria:
inclusion criteria: * 2nd or the 3rd trimester ultrasound examination realized at the hospital "femme mère enfant" in lyon between 2008 and 2015 * isolated transverse cerebellar diameter \<5th centile * parents who received the information and did not object to participate to the study exclusion criteria: * decreased transverse cerebellar diameter with associated malformations diagnosed during prenatal period * family history of neurodevelopmental delay or cognitive impairment * preterm delivery (\< 28 wg) * severe restriction in growth at birth (\<3e centile) * neonatal asphyxia (ph blood cord \< 7) * apgar score \< 7 at 5 min of live with transfer to the neonatal intensive care unit